标题
T cell-engaging therapies — BiTEs and beyond
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-04-02
DOI
10.1038/s41571-020-0347-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint
- (2020) Mutlu Hizal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for small cell lung cancer: mechanisms of resistance
- (2019) Gerhard Hamilton et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Circulating Tumor DNA: A Step into the Future of Cancer Management
- (2019) Joana Fernandes Marques et al. ACTA CYTOLOGICA
- Liquid Biopsy: General Concepts
- (2019) Geoffroy Poulet et al. ACTA CYTOLOGICA
- Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.
- (2019) Mark Rosenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
- (2019) Horst-Dieter Hummel et al. JOURNAL OF CLINICAL ONCOLOGY
- Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
- (2019) Hervé Dombret et al. LEUKEMIA & LYMPHOMA
- Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
- (2019) Amber C. King et al. LEUKEMIA RESEARCH
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours
- (2019) Kate L. Lowe et al. CANCER TREATMENT REVIEWS
- A FIRST-IN-HUMAN STUDY OF A HALF-LIFE EXTENDED CD19-TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA
- (2019) L. Popplewell et al. HEMATOLOGICAL ONCOLOGY
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
- (2019) Thomas E. Delea et al. PHARMACOECONOMICS
- Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
- (2019) Thomas Nerreter et al. Nature Communications
- Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
- (2019) Elias J. Jabbour et al. CANCER
- Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
- (2019) Matthias Klinger et al. CANCER RESEARCH
- Immune checkpoint inhibition for the treatment of renal cell carcinoma
- (2019) Viktoria Stühler et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
- (2019) Hsiang‐Fong Kao et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
- (2019) Johanna Veldman et al. CANCER TREATMENT REVIEWS
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
- (2018) Tobias Speck et al. CLINICAL CANCER RESEARCH
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
- (2018) Colin E. Correnti et al. LEUKEMIA
- Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
- (2018) Xiling Jiang et al. mAbs
- Development of MGD007, a gpA33 x CD3 bispecific DART® protein for T-cell immunotherapy of metastatic colorectal cancer
- (2018) Paul A Moore et al. MOLECULAR CANCER THERAPEUTICS
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
- (2018) Clare Y. Slaney et al. Cancer Discovery
- Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
- (2018) Anna Wing et al. Cancer Immunology Research
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
- (2018) Anthony S. Stein et al. ANNALS OF HEMATOLOGY
- Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.
- (2018) Takami Sato et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome: grading, modeling, and new therapy
- (2018) Delong Liu et al. Journal of Hematology & Oncology
- Strategies to Address Chimeric Antigen Receptor Tonic Signaling
- (2018) Adam Ajina et al. MOLECULAR CANCER THERAPEUTICS
- Strategies for Predicting Response to Checkpoint Inhibitors
- (2018) Roberta Zappasodi et al. Current Hematologic Malignancy Reports
- Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
- (2018) Amanda Rosewell Shaw et al. Frontiers in Immunology
- Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
- (2018) Sebastian Kobold et al. Frontiers in Oncology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
- (2018) Monika Herrmann et al. BLOOD
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- CD19-directed CAR T cells gain traction
- (2018) Stephen J Schuster LANCET ONCOLOGY
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innate and adaptive immunity combined for cancer treatment
- (2018) Sebastian Kobold PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Making CAR T Cells a Solid Option for Solid Tumors
- (2018) Andrea Schmidts et al. Frontiers in Immunology
- Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
- (2017) Nicola Gökbuget et al. HAEMATOLOGICA
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
- (2017) Mingxue Fan et al. Journal of Hematology & Oncology
- PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination
- (2017) Arash Memarnejadian et al. JOURNAL OF IMMUNOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses
- (2017) Eleanor M. Scott et al. MACROMOLECULAR BIOSCIENCE
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
- (2017) Lucas A. Horn et al. Oncotarget
- Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
- (2017) Nicola Gökbuget et al. HAEMATOLOGICA
- Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
- (2017) Thomas E. Delea et al. JOURNAL OF MEDICAL ECONOMICS
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
- (2016) Liqin Liu et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
- (2016) Min Zhu et al. CLINICAL PHARMACOKINETICS
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
- (2016) Marina Bacac et al. OncoImmunology
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
- (2016) Marco Ruella et al. Computational and Structural Biotechnology Journal
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- ImmTACs for targeted cancer therapy: Why, what, how, and which
- (2015) Joanne Oates et al. MOLECULAR IMMUNOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
- (2015) Josep-Maria Josep-Maria Ribera et al. OncoTargets and Therapy
- CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
- (2015) Alexander J. Davenport et al. Cancer Immunology Research
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Monoclonal TCR-redirected tumor cell killing
- (2012) Nathaniel Liddy et al. NATURE MEDICINE
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
- (2010) Peter Ruf et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
- (2009) R. Bassan et al. BLOOD
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
- (2009) Dirk Nagorsen et al. LEUKEMIA & LYMPHOMA
- Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
- (2008) Jessica B. Katz et al. IMMUNOLOGICAL REVIEWS
- Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
- (2008) Peter Bader et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started